Evaluating a Novel Drug for Lymphoma
Lymphoma accounts for an estimated 25 percent of all canine cancers. This study investigates a new therapeutic antibody that appears to effectively kill canine lymphoma cells but does not appear to result in serious side effects. Researchers will work to find the best dosage and evaluate the drug’s safety and effectiveness in dogs with B-cell lymphoma.
Co-sponsored with the Morris Animal Foundation, Grant Number: D12CA-033
Barbara Biller, DVM, PhD
Diplomate ACVIM (Oncology)
Colorado State University